Search the Newsreel

Aligos Therapeutics Company Profile & Introduction

This document is intended to provide a company profile and introduction for Aligos Therapeutics. Further details about the company's operations, financial performance, and strategic direction would typically be included in a complete profile.

Gossamer Bio Announces Second Quarter 2026 Financial Results and Provides Business Update

Gossamer Bio announced its Q2 2026 financial results and provided a business update, highlighting its progress toward an NDA submission for seralutinib in PAH by September 2026. The company reacquired worldwide development and commercial rights for seralutinib and significantly reduced its debt through a …

Gossamer Bio (GOSS) Reports Q2 Loss, Tops Revenue Estimates

Gossamer Bio (GOSS) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.17 per share a year ago. These figures are adjusted for non-recurring items. This quarterly …

Gossamer Bio earnings beat by $0.04, revenue topped estimates

Gossamer Bio: Q2 Earnings Snapshot

Gossamer Bio (GOSS) cuts debt but flags going concern and liquidity strain

Gossamer Bio, Inc. 2026: Revenue $9.24M, Net income $16.9M, EPS ($0.08) — 10-Q Summary

Gossamer Bio, Inc. reported its current quarter 2026 financial results, showing revenue of $9.24 million and a net income of $16.9 million, a significant improvement from a net loss in the prior year. The company also highlighted positive Phase 3 clinical trial results for …

Gossamer Bio Inc (GOSS) News, Articles, Events & Latest Updates

Gossamer Bio Inc (GOSS) recently reported its Q2 2026 financial results, showing a loss but exceeding revenue estimates. The company, a clinical-stage biopharmaceutical firm, is focusing on developing seralutinib for pulmonary arterial hypertension. Several legal firms are investigating the company, and its stock has …

4 Goldman Sachs Mutual Funds to Buy for Wealth Creation

The U.S. economy is showing a mixed picture this month, with the labor market losing momentum even as some indicators remain resilient. July nonfarm payrolls fell by 23,000, far below expectations for an 83,000 gain, while previous months were revised sharply lower. The unemployment …

Only 12% of family businesses stay in the family by the third generation. A Goldman Sachs chairman says optimism is the reason

Only about 12% of family-owned businesses make it to a third generation still under family control, according to a new Goldman Sachs playbook aimed at the founders and dynasties the bank counts among its most prized clients. It's a statistic Goldman itself put in …

Should Goldman Sachs MarketBeta U.S. 1000 Equity ETF (GUSA) Be on Your Investing Radar?

If you're interested in broad exposure to the Large Cap Blend segment of the US equity market, look no further than the Goldman Sachs MarketBeta U.S. 1000 Equity ETF (GUSA), a passively managed exchange traded fund launched on April 5, 2022. The fund is …

Aligos Therapeutics, Inc. (ALGS) Stock Price, News, Quote & History

Industry Analysts Just Made A Stunning Upgrade To Their Aligos Therapeutics, Inc. (NASDAQ:ALGS) Revenue Forecasts

Industry analysts have significantly upgraded their revenue forecasts for Aligos Therapeutics, Inc. (NASDAQ:ALGS) for 2026, projecting a 15% improvement in sales to US$36 million, up from a previous estimate of US$22 million. Concurrently, the expected loss per share has been reduced by 46% to …

Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China

Aligos Therapeutics announced that its partner Amoytop has dosed the first participant in a Phase 1 study of ALG-170675 in China. This investigational antisense oligonucleotide (ASO) is designed for the functional cure of chronic hepatitis B virus (HBV) infection, aiming to improve cure rates …

Aligos begins phase 1 trial of hepatitis B treatment in China

Aligos Therapeutics Inc. has initiated a Phase 1 study in China for ALG-170675, an antisense oligonucleotide aimed at treating chronic hepatitis B virus infection. This study, conducted in collaboration with Xiamen Amoytop Biotech Co., Ltd., will assess the drug candidate's safety, tolerability, pharmacokinetics, and …

The Goldman Sachs Group (GS)’s $2.3 Billion ETF Bet: How Does It Compare With JPMorgan?

The Goldman Sachs Group, Inc. (NYSE:GS)–NEOS deal looks strategically important because it pushes Goldman further into a part of asset management that is growing quickly: actively managed ETFs, particularly products that use options to generate income and manage downside risk. Goldman is paying up …

Aligos Begins Testing a Chronic Hepatitis B Candidate in China

Aligos Therapeutics announced that its partner Xiamen Amoytop Biotech has dosed the first participant in a Phase 1 study of ALG-170675 in China. This investigational antisense oligonucleotide aims for a functional cure of chronic hepatitis B virus (HBV) infection. The trial will assess safety, …

GOSS News | GOSSAMER BIO INC (NASDAQ:GOSS)

Goldman Sachs Stock Rises After $2.25 Billion ETF Deal

This article first appeared on GuruFocus. Goldman Sachs (NYSE:GS), the Wall Street heavyweight spanning investment banking and asset management, agreed Wednesday to buy NEOS Investments for as much as $2.25 billion. Goldman shares rose approximately 0.7% by late morning, but the bigger story is …

Goldman Sachs to Acquire ETF Provider Neos in $2.3 Billion Deal

Goldman Sachs Group will pay as much as $2.25 billion to buy Neos Investments, expanding its asset manager's reach in the actively managed exchange-traded fund market. Bloomberg's Neil Sipes joins to discuss. View Comments

Goldman Sachs Expands Active ETF Push with $2.25 Billion Neos Acquisition

The company says it will buy Neos Investments, which specializes in funds that use options-based strategies to generate income. Continue Reading

Goldman Sachs to Buy Neos Investments for $2.25 Billion

Goldman Sachs Group will pay as much as $2.25 billion to buy Neos Investments, expanding its asset manager's reach in the actively managed ETF market. Katherine Doherty reports on "Bloomberg Open Interest." View Comments

Goldman Sachs (GS) Agrees $2.25 Billion ETF Acquisition

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Goldman Sachs Group (NYSE: GS) agreed to acquire ETF provider NEOS Investments for US$2.25b in a deal focused on options-based income products. The …

Goldman Sachs to acquire Neos for up to $2.25b cash and stock

Investing.com -- Goldman Sachs Group Inc. will pay up to $2.25 billion to acquire Neos Investments, expanding its presence in the actively managed exchange-traded fund market, according to a Bloomberg report early Wednesday. The cash-and-equity transaction will bring a growing ETF issuer into the …

Goldman Sachs to buy ETF provider Neos in $2.3 billion deal

Aug 12 (Reuters) - Goldman Sachs will acquire exchange-traded funds provider Neos ‌Investments for as much as $2.25 ‌billion, as the investment bank looks to ​bolster its presence in asset management. Neos, which provides ETFs on systematic options-based income, managed $30 billion in assets …

Goldman Sachs (GS) Stock May Be A Bargain On Earnings But Fairly Valued Overall

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Goldman Sachs Group stock has put in a very strong three year run, yet current valuation checks suggest the shares now sit closer …

The Bull Case For Goldman Sachs Group (GS) Could Change Following NVIDIA’s $500B AI Compute Financing Push

In August 2026, NVIDIA announced it had signed memorandums of understanding with Goldman Sachs and five other major financial institutions to create independent compute financing platforms that could mobilize over US$500.00 billion of third-party capital for AI infrastructure across its ecosystem, subject to final …

Goldman's M&A Leadership Bodes Well: Should You Buy GS Stock Now?

The Goldman Sachs Group, Inc. GS continues to strengthen its position in the global dealmaking landscape, with its latest merger and acquisition (M&A) league-table performance underscoring the depth of its investment-banking (IB) franchise. Goldman ranked the top financial adviser on mergers and acquisitions in …

Goldman Sachs warns AI investment may be crowding out other business spending

Investing.com -- Goldman Sachs said the surge in artificial intelligence spending may be crowding out other business activity, though it found only limited evidence of that effect so far. In a note to clients, analyst Jessica Rindels estimated AI investment in the U.S. will …

Jim Cramer Recommends Goldman Sachs and Morgan Stanley to Profit From Accelerating M&A Deals

During Mad Money's August 6 episode, host Jim Cramer highlighted why investors should target elite advisory firms rather than speculating on acquisition targets, as he said: Here's a big theme that right now really only impacts two large companies: pent-up demand for mergers and …

Kuehn Law Encourages Investors of Gossamer Bio, Inc. to Contact Law Firm

Kuehn Law is investigating whether officers and directors of Gossamer Bio, Inc. (GOSS) breached their fiduciary duties due to alleged misrepresentations about its Phase 3 PROSERA study. The lawsuit claims the company failed to disclose issues with the study's design, leading to artificially inflated …

3 Top-Ranked Goldman Sachs Mutual Funds for Significant Returns

Goldman Sachs Asset Management (GSAM) is a global company that has been providing investment management, portfolio design and advisory services to individual and institutional investors worldwide since 1988. Its strategies span asset classes, industries and geographies. As of Dec. 31, 2025, GSAM had $3.6 …

H.C. Wainwright reiterates Aligos stock rating on HBV progress

H.C. Wainwright reaffirmed a Buy rating and $50 price target for Aligos Therapeutics Inc. (NASDAQ:ALGS) following positive updates on its chronic hepatitis B virus infection treatments, including breakthrough therapy designation for pevifoscorvir sodium in China and complete enrollment of the Phase 2 B-SUPREME trial. …